U.S. Stem Cell to focus on and expand in-clinic therapies

Courtesy of Kristin Comella (CSO) of U.S. Stem Cell, Inc.

Sunrise, FL – June 19, 2017 – (OTC:USRM) U.S. Stem Cell, Inc., a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, announces an aggressive plan to expand an additional 12 stem cell treatment centers and clinics in the US.  US Stem Cell has been in discussions with the FDA regarding Regenerative Medicine Advanced Therapy (RMAT) Designation for the Myocell product and at this time, the company has decided not to further invest in RMAT Designation and instead invest and focus on our in-clinic therapies for patients.

According to the 21st Century Cures Act, within one year of enactment, the FDA must issue draft guidance clarifying how the FDA will evaluate devices used in the  recovery, isolation, or delivery of regenerative advanced therapies. Until this guidance document is published, it is unclear how this regulation will affect the MyoCell program. Until then, U.S. Stem Cell will focus on opening new clinics around the country to better serve patients in need.  In addition to the original Sunrise clinic (that has successfully treated hundreds of patients and generated over $2m in revenues in the past 12 months alone), recent clinic openings include Miami and Palm Beach, Florida.  Upcoming openings include Dallas, Texas (thanks in part to the early adoption of patient rights by the State of Texas), Chicago, Atlanta and Denver—as well as other clinics in the northeast and the west coast.

U.S. Stem Cell will focus on our revenue generating programs that are treating patients NOW–which have successfully helped over 7000 patients thus far.  Our company was founded in 1999 and has completed more clinical treatments (for both humans and animals) than any other regenerative medicine company in the world.  In addition to our efforts at US Stem Cell Training and VetBiologics, our focus will be expanding and opening additional clinics throughout the U.S. to offer these cutting edge technologies to more patients.

.................................................................................................................................................................

Basics about Stem Cell Therapy From the Source - 
by Dr. Kristin Comella

Every one of us has stem cells in our body working all the time in every tissue ready to repair any damage.   For injuries, the process of REGENERATIVE MEDICINE allows us to harness your own stem cells from one part of your body and relocate them to the
area where you need them more.  The technology to heal is inside you.  Harness your own body’s healing capacity.

DOCTORS DISCOVER THE MIGRAINE GENOME

by: Dr. Andrew J. Rochman

More than 10% of the people in the world complain about crippling migraines. Migraines can be extremely difficult to deal with and may even hinder people from functioning normally. Symptoms of a migraine include throbbing, intense pain, nausea and an extreme sensitivity to light and sound which can last from a few hours to a few days.

An Elusive Cure
Up until now a migraine cure has been rather elusive. Sufferers of migraines were traditionally told to stay away from factors which may trigger their migraines such as stress, bright lights, foods, or certain exercises.
Migraine is one of the most common disabling disorders in the world. Locating the problems behind illnesses such as migraines and epilepsy is much more complex than it seems. This is because the patient does not have any neural responses to the illness until an episode occurs which makes it problematic to detect biochemical clues.

A Cure for the Disabling Disorder

Recently, researchers were able to uncover 5 genetic regions which were linked to migraines. The location and understanding of these genetic regions has brought researchers closer to understanding the biomarkers or triggers which cause migraines. Another large scale study was able to locate 12 genetic regions out of which 8 regions were located in the cranial areas which control the circuitries of the brain. 2 of the genetic regions control the maintenance of healthy brain tissue.

The Genome

Additionally, another research by Oxford University found that a gene called TRESK was the root cause of migraines. This gene is what controls the sensitivity pain. As the threshold is lowered the ability to perceive pain is increased and leads to a difficulty in functioning because of the constant awareness of pain. Since awareness of all associated factors is raised, migraine sufferers also experience an increased sensitivity to light, sounds and touch.

Who is at Risk?

Researchers found that individuals that carried a variant of Chromosome 8 in two genes were more likely to develop migraines. The two genes; PGCP and MTDH/AEG-1 which carried the DNA variant were associated with the regulation of glutamate levels. These levels are tasked with the transportation of messages between the brain and nerve cells. An accumulation of glutamate in the synapses of nerve cells is what triggers migraines. 
This is what became the target area for researchers looking to find a cure for migraine. If the glutamate buildup in the synapse can be prevented, then migraines can be effectively reduced or even eliminated.

Future Implications of the Research

The discovery of a migraine cure and the alleviation of associated symptoms could serve as a gateway for the treatment of other related illnesses. According to Dr. Melody Winawer who was part of the research, no disorder is a standalone ailment. By finding a cure for migraine, there is a possibility of locating the problems behind other intersecting neural disorders such as anxiety, depression, epilepsy, psychosis, and suicidality.
The study may even lead to an upheaval of the treatment methods that we know today as recognition, prevention, diagnosis, and treatment are transformed.

.